Shenzhen Enduring Biotech, LTD. (abbr. as Enduring) was founded in July 2018. Enduring is an innovative company that develops antibody related drugs, mainly focusing on cancer treatment and autoimmune diseases such as chronic inflammatory diseases. Founders of the company have extensive experience of PEGylation technology, protein engineering and successful drug development, which ensures the sustainable growth of the company and development of innovative biological medicines. Enduring is committed to develop differentiated antibody technology aiming unmet clinical needs. The company has two technology platforms: PEGylated T-cell engager Bispecific Antibody (P-T-BsAb) technology platform and PEGylated Bispecific ADC (P-BsADC) technology platform. Both platforms enable the company to rapidly develop novel antibody related drugs.